IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
about
Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5pAssociation of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.Association between higher expression of interleukin-8 (IL-8) and haplotype -353A/-251A/+678T of IL-8 gene with preeclampsia: A case-control study.Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.PharmGKB summary: pazopanib pathway, pharmacokinetics.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.The genetics of drug efficacy: opportunities and challenges.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Precision medicine from the renal cancer genome.Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma.Role of Intracystic Cytokines and Nitric Oxide in Ovarian Neoplasms.Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up?
P2860
Q35918018-6FFB45AD-F64B-4B53-A4E9-1CBAA28887FBQ36275134-4E23F914-6B94-4ED0-BB97-99627C0ECE97Q36893510-8F84F060-B8E4-4772-8080-D9BE9751EE0AQ37552080-D54674C6-051D-4FD7-886C-BB92CF6776BCQ38546217-52B7F2C5-948B-4C60-BC25-B9CED02CF875Q38693146-DB079B05-D80A-4A39-9D4E-AB20B9BA425DQ38720430-C947096D-5D41-4A3E-BF64-DA12E446A321Q38773033-C9EA4938-CFEB-44BB-8912-2F697E8ABAE6Q38936104-2B42C758-A92F-45DD-BE26-FA77A5ABFA31Q38970282-47A5EBF1-789B-4314-AA54-2B67E25E01E6Q40177329-46C37989-175B-44C5-94DF-CD04B44007C0Q41595498-D0CB9D44-88C2-413F-9FB3-4808F2892D75Q47727375-23F28F6E-6928-43EF-953E-34A955015ACDQ48306032-1879D301-0D4A-4425-98F3-4D3881BF033CQ53448682-13684A89-4B8E-439A-A9FB-14F6A2E5FA50
P2860
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
IL8 polymorphisms and overall ...... nts with renal cell carcinoma.
@ast
IL8 polymorphisms and overall ...... nts with renal cell carcinoma.
@en
type
label
IL8 polymorphisms and overall ...... nts with renal cell carcinoma.
@ast
IL8 polymorphisms and overall ...... nts with renal cell carcinoma.
@en
prefLabel
IL8 polymorphisms and overall ...... nts with renal cell carcinoma.
@ast
IL8 polymorphisms and overall ...... nts with renal cell carcinoma.
@en
P2093
P2860
P50
P356
P1476
IL8 polymorphisms and overall ...... nts with renal cell carcinoma.
@en
P2093
C F Spraggs
C N Sternberg
L N Pandite
T K Choueiri
P2860
P2888
P304
P356
10.1038/BJC.2015.64
P407
P50
P577
2015-03-31T00:00:00Z